meta|Evidence - COVID-19
darunavir/cobicistat plus chloroquine
anticoagulant, curative dose 3
anticoagulant, prophylactic dose 4
anticoagulation, intermediate prophylactic dose 1
anti-inflammatoty and immuno-therapy
non-steroidal anti-inflammatory drugs 5
convalescent plasma treatment 21
inactivated mycobacterium vaccine
recombinant super-compound interferon rSIFN-co 1
SNG001 inhaled interferon beta 1
bamlanivimab plus etesevimab 3
BRII-196 and BRII-198 (Brii Biosciences)
casirivimab and imdevimab (REGN-COV2) 1
regdanvimab (CT-P59 Celltrion) 1
anakinra 3
sarilumab azithromycin hydroxychloroquine
tocilizumab 24
Polyinosinic-Polycytidylic Acid
antiviral and associated therapy
azvudine 1
favipiravir 15
hydroxychloroquine plus macrolides 8
ivermectin 27
lopinavir / ritonavir plus ribavirin
lopinavir/ritonavir plus interferon ß-1a
lopinavir/ritonavir, ribavirin and interferon beta-1b 1
Renin-angiotensin-system-acting agents 7
angiotensin converting enzyme inhibitors (ACEIs)
angiotensin receptor blockers (ARBs) 2
continuous positive airway pressure (CPAP)
nitric oxide (gas Inhalation or releasing solution)
proton pump inhibitors (PPI) 6
zinc 3
This project is supported by a grant of the French Ministry of Health (Hospital Clinical Research Program, PHRC-N) and self-funded by Hospices Civils de Lyon, CNRS UMR5558 LBBE University Lyon-1.
![]() |
![]() |
![]() |
-
About
-
Our approach
-
Credits
Made with in Lyon
-
Contact us
-
Privacy policy
-